Last reviewed · How we verify
Upadacitinib Oral Product
Upadacitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which play a key role in the inflammatory response.
Upadacitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which play a key role in the inflammatory response. Used for Rheumatoid arthritis, Psoriatic arthritis, Juvenile idiopathic arthritis.
At a glance
| Generic name | Upadacitinib Oral Product |
|---|---|
| Sponsor | McMaster University |
| Drug class | JAK inhibitor |
| Target | JAK |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting JAK enzymes, upadacitinib reduces the production of pro-inflammatory cytokines and mediators, thereby decreasing inflammation and modulating the immune response. This mechanism of action is thought to contribute to its therapeutic effects in various inflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Psoriatic arthritis
- Juvenile idiopathic arthritis
- Atopic dermatitis
Common side effects
- Upper respiratory tract infections
- Nausea
- Headache
- Diarrhea
- Musculoskeletal pain
Key clinical trials
- Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (PHASE3)
- Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. (PHASE3)
- Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ Tablets
- A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (PHASE3)
- A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (PHASE3)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis (PHASE3)
- A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Upadacitinib Oral Product CI brief — competitive landscape report
- Upadacitinib Oral Product updates RSS · CI watch RSS
- McMaster University portfolio CI